ClinicalTrials.gg
CompletedNCT06813924Updated Sep 29, 2026

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

A Phase 1 interventional study of Etavopivat and Digoxin in Healthy Volunteers Sickle Cell Disease, Thalassemia, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies in Thalassemia with a site in United States — 9 open to participants now, 20 under way, 8 of them phase 3. Thalassemia · United States.

Enrollment
26th of 81
37 · median 24
Started
2025
with 3 others
Phase 1
14 of 104
1 open now
Registered
100th of 104
by date
Lead sponsor
4 of 104
Novo Nordisk A/S

Among the 104 studies in Thalassemia with a site in United States, this one is the 26th largest by enrollment of the 81 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 in phase 1, and was the 100th registered.

Thalassemia

251 studies on the registry are indexed under Thalassemia; 44 are open to participants now.

Browse Thalassemia studies →

Open to participants now

9 of the 104 studies in Thalassemia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Thalassemia with a site in United States, or all of them as a file.
02

Study summary

The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.

03

Conditions studied

  • Healthy Volunteers Sickle Cell Disease, Thalassemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.5 and 29.9 kilograms per square meter (kg/m\^2) (both inclusive) at screening.
  • Body weight greater than (>) 50.0 kg at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study interventions or related products.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • Exposure to an medicinal product within 30 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
  • Participant is unable to refrain from or anticipates the use of any drug known to be a moderate or strong inhibitor or inducer of uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, , CYP2C9, MATE1, OATP1B1/1B3, BCRP, OCT2, or P-gp, including St. John's Wort for 28 days prior to dosing and throughout the study.
  • Use of any medication with unknown or unspecified content within 90 days before screening.
  • Use of or intent to use prescription medicinal products or non-prescription drugs (including vitamins and herbal supplements) within 14 days prior to dosing and throughout the study, as declared by the participant, except for:
  • Adequate contraceptive methods.
  • Hormone replacement therapy (HRT) (for menopausal females).
  • Over-the-counter topical medications known to not reach systemic circulation.
  • Occasional use of acetaminophen up to 2 grams (g) (4 x 0.5 g) daily.
  • Not able or not willing to adhere to study procedures, including:
  • Eating the food provided in the study.
  • Refraining from ingesting food or drinks that are not allowed during the study.
  • Swallowing tablets.
  • Abstaining from concomitant medication not allowed during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Period 1: digoxin+pitavastatin+metformin

    Participants will receive a single dose of oral digoxin, pitavastatin and metformin.

    Drug: Digoxin · Drug: Pitavastatin · Drug: Metformin

  • Experimental
    Period 1: midazolam+rosuvastatin

    Participants will receive a single dose of oral midazolam and rosuvastatin.

    Drug: Midazolam · Drug: Rosuvastatin

  • Experimental
    Period 2: etavopivat+midazolam

    Participants will receive a daily dose of oral etavopivat and single dose of oral midazolam.

    Drug: Etavopivat · Drug: Midazolam

  • Experimental
    Period 2: etavopivat+midazolam+rosuvastatin

    Participants will receive a daily dose of oral etavopivat, single dose of oral midazolam and rosuvastatin.

    Drug: Etavopivat · Drug: Midazolam · Drug: Rosuvastatin

  • Experimental
    Period 2: etavopivat+digoxin+pitavastatin+metformin

    Participants will receive a daily dose of oral etavopivat, single dose of oral digoxin, pitavastatin and metformin.

    Drug: Etavopivat · Drug: Digoxin · Drug: Pitavastatin · Drug: Metformin

Interventions

  • Participants will receive a daily dose of etavopivat orally.

  • Participants will receive a single dose of digoxin orally.

  • Participants will receive a single dose of pitavastatin orally.

  • Participants will receive a single dose of metformin orally.

  • Participants will receive a single dose of midazolam orally.

  • Participants will receive a single dose of rosuvastatin orally.

06

What researchers measure

Primary outcomes

  1. Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state

    Measured as picograms per milliliter (pg/mL).

    Time frame: Day 1 and day 3 after digoxin administration

  2. AUC0-inf, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state

    Measured as hours\*picograms per milliliter (h\*pg/mL).

    Time frame: Day 1 and day 3 after digoxin administration

  3. Cmax, rosuvastatin, SD: Maximum observed rosuvastatin plasma concentration with and without etavopivat at steady state

    Measured as pg/mL.

    Time frame: Day 1 after rosuvastatin administration

  4. AUC0-inf, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state

    Measured as h\*pg/mL.

    Time frame: Day 1 after rosuvastatin administration

  5. Cmax, midazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as pg/mL.

    Time frame: Day 1 after midazolam administration

  6. AUC0-inf, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as h\*pg/mL.

    Time frame: Day 1 after midazolam administration

  7. Cmax, pitavastatin, SD: Maximum observed pitavastatin plasma concentration with and without etavopivat at steady state

    Measured as nanograms per milliliter (ng/mL).

    Time frame: Day 1 and day 3 after pitavastatin administration

  8. AUC0-inf, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state

    Measured as hours\*nanograms per milliliter(h\*ng/mL).

    Time frame: Day 1 and day 3 after pitavastatin administration

  9. Cmax, metformin, SD: Maximum observed metformin plasma concentration with and without etavopivat at steady state

    Measured as ng/mL.

    Time frame: Day 1 and day 3 after metformin administration

  10. AUC0-inf, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state

    Measured as h\*ng/mL.

    Time frame: Day 1 and day 3 after metformin administration

Secondary outcomes

  1. AUC0-last, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state

    Measured as h\*pg/mL.

    Time frame: Day 1 and day 3 after digoxin administration

  2. t1/2, digoxin, SD: Terminal half-life for digoxin with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after digoxin administration

  3. tmax, digoxin, SD: Time to maximum observed digoxin plasma concentration with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after digoxin administration

  4. CL/Fdigoxin, SD: Apparent plasma clearance of digoxin with and without etavopivat at steady state

    Measured as liters per hour (L/h).

    Time frame: Day 1 and day 3 after digoxin administration

  5. Vz/Fdigoxin, SD: Apparent volume of distribution of digoxin with and without etavopivat at steady state based on plasma concentration values

    Measured as liters (L).

    Time frame: Day 1 and day 3 after digoxin administration

  6. AUC0-last, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state

    Measured as h\*pg/mL.

    Time frame: Day 1 after rosuvastatin administration

  7. t1/2, rosuvastatin, SD: Terminal half-life for rosuvastatin with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 after rosuvastatin administration

  8. tmax, rosuvastatin, SD: Time to maximum observed rosuvastatin plasma concentration with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 after rosuvastatin administration

  9. CL/Frosuvastatin, SD: Apparent plasma clearance of rosuvastatin with and without etavopivat at steady state

    Measured as L/h.

    Time frame: Day 1 after rosuvastatin administration

  10. Vz/Frosuvastatin, SD: Apparent volume of distribution of rosuvastatin with and without etavopivat at steady state based on plasma concentration values

    Measured as L.

    Time frame: Day 1 after rosuvastatin administration

  11. AUC0-last, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours to the last quantifiable concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as h\*pg/mL.

    Time frame: Day 1 after midazolam administration

  12. t1/2, midazolam, SD: Terminal half-life for midazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 after midazolam administration

  13. tmax, midazolam, SD: Time to maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 after midazolam administration

  14. CL/Fmidazolam, SD: Apparent plasma clearance of midazolam without etavopivat, with a single dose of etavopivat and with etavopivat at steady state

    Measured as L/h.

    Time frame: Day 1 after midazolam administration

  15. Vz/Fmidazolam, SD: Apparent volume of distribution of midazolam without etavopivat, with a single dose of etavopivat and with etavopivat at steady state

    Measured as L.

    Time frame: Day 1 after midazolam administration

  16. AUC0-inf, 1-hydroxymidazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as h\*pg/mL.

    Time frame: Day 1 after midazolam administration

  17. Cmax, 1-hydroxymidazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as pg/mL.

    Time frame: Day 1 after midazolam administration

  18. AUC0-last, 1-hydroxymidazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours to the last quantifiable concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as h\*pg/mL.

    Time frame: Day 1 after midazolam administration

  19. t1/2, 1-hydroxymidazolam: Terminal half-life for 1-hydroxymidazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 after midazolam administration

  20. tmax, 1-hydroxymidazolam: Time to maximum observed 1-hydroxymidazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 after midazolam administration

  21. CL/F1-hydroxymidazolam: Apparent plasma clearance of 1-hydroxymidazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as L/h.

    Time frame: Day 1 after midazolam administration

  22. Vz/F1-hydroxymidazolam: Apparent volume of distribution of 1-hydroxymidazolam based on plasma concentration values without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state

    Measured as L.

    Time frame: Day 1 after midazolam administration

  23. AUC0-last, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state

    Measured as h\*ng/mL.

    Time frame: Day 1 and day 3 after pitavastatin administration

  24. t1/2, pitavastatin, SD: Terminal half-life for pitavastatin with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after pitavastatin administration

  25. tmax, pitavastatin, SD: Time to maximum observed pitavastatin plasma concentration with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after pitavastatin administration

  26. CL/Fpitavastatin, SD: Apparent plasma clearance of pitavastatin with and without etavopivat at steady state

    Measured as L/h.

    Time frame: Day 1 and day 3 after pitavastatin administration

  27. Vz/Fpitavastatin, SD: Apparent volume of distribution of pitavastatin with and without etavopivat at steady state based on plasma concentration values

    Measured as L.

    Time frame: Day 1 and day 3 after pitavastatin administration

  28. AUC0-last, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state

    Measured as h\*ng/mL.

    Time frame: Day 1 and day 3 after metformin administration

  29. t1/2, metformin, SD: Terminal half-life for metformin with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after metformin administration

  30. tmax, metformin, SD: Time to maximum observed metformin plasma concentration with and without etavopivat at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after metformin administration

  31. CL/Fmetformin, SD: Apparent plasma clearance of metformin with and without etavopivat at steady state

    Measured as L/h.

    Time frame: Day 1 and day 3 after metformin administration

  32. Vz/Fmetformin, SD: Apparent volume of distribution of metformin with and without etavopivat at steady state based on plasma concentration values

    Measured as L.

    Time frame: Day 1 and day 3 after metformin administration

  33. Aelast, metformin, SD%: Percentage of the metformin excreted into urine from the time of dosing to the collection time of the last measurable concentration with and without etavopivat at steady state

    Measured as percentage (%) of the metformin excreted into urine.

    Time frame: Day 1 and day 3 after metformin administration

  34. CLR, metformin, SD: Renal clearance of metformin

    Measured as L/h.

    Time frame: Day 1 and day 3 after metformin administration

  35. AUC0-tau, etavopivat: Area under the etavopivat plasma concentration-time curve during one dosing interval at single dose and at steady state

    Measured as h\*ng/mL.

    Time frame: Day 1 and day 3 after etavopivat administration

  36. AUC0-last etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours to the last quantifiable concentration at single dose and at steady state

    Measured as h\*ng/mL.

    Time frame: Day 1 and day 3 after etavopivat administration

  37. Cmax, etavopivat: Maximum observed etavopivat plasma concentration at single dose and at steady state

    Measured as ng/mL.

    Time frame: Day 1 and day 3 after etavopivat administration

  38. t1/2, etavopivat: Terminal half-life for etavopivat at single dose and at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after etavopivat administration

  39. tmax, etavopivat: Time to maximum observed etavopivat plasma concentration at single dose and at steady state

    Measured as hours.

    Time frame: Day 1 and day 3 after etavopivat administration

  40. V/Fetavopivat: Apparent volume of distribution of etavopivat based on plasma concentration values at single dose and at steady state

    Measured as L.

    Time frame: Day 1 and day 3 after etavopivat administration

  41. CL/Fetavopivat: Apparent plasma clearance of etavopivat at single dose and at steady state

    Measured as L/h.

    Time frame: Day 1 and day 3 after etavopivat administration

  42. C, etavopivat: Observed etavopivat plasma concentration after single and multiple doses

    Measured as ng/mL.

    Time frame: From day 1 to day 4 after administration of etavopivat

  43. Number of adverse events (AEs)

    Measured as count of events.

    Time frame: From first dose (day 1) until end of study (day 32)

07

Study locations

1 site
  • ICON-Salt Lake City
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in May 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 7, 2025
StartActual
Feb 6, 2025
Primary completionActual
May 27, 2025
CompletionActual
May 27, 2025
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06813924
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Feb 6, 2025
Primary completion
May 27, 2025
Completion
May 27, 2025
Last update
Sep 29, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etavopivat · Digoxin · Pitavastatin · Metformin · Midazolam · Rosuvastatin

Start the discussion